Moxie CEO Hopes to Score Coveted N.J. Medical Pot License
*By Carlo Versano*
The competition is on for new medicinal marijuana licenses in New Jersey after Democratic Gov. Phil Murphy prioritized cannabis production when he took office. The CEO of one potential licensee, Moxie, thinks the state has "passed the tipping point" for accepting medical pot at the state level.
Jordan Lams, founder and CEO of the medicinal marijuana producer, told Cheddar as he awaited news on whether his company had been awarded one of the licenses that Moxie has a fully built-out, 16-acre farm and greenhouse operation at the ready ー which would help New Jersey get its operations up to scale quickly.
"The state can count on us to do what we say we will," he said.
Lams praised Gov. Murphy for "taking ownership" of medical marijuana policy after it had languished under previous administrations.
There is now so much pent-up demand from patients Lams said, that the state has concerns over shortages.
The license that Moxie hopes to win is a fully-integrated, "seed-to-sale" license, though Lams said he will also apply for licenses to just grow and process, if this one is not granted.
Lams, who started a career in medical marijuana after his younger sister died of leukemia, now advocates for responsible regulations in the nascent cannabis industry.
He said he's seeing a market that's "developing every day."
"Every day someone who never would have touched this before is really coming into the marketplace. It's global at this point."
For full interview [click here](https://cheddar.com/videos/moxie-vies-for-nj-medicinal-marijuana-license).
The global chip shortage continues to weigh on the automotive industry. For example, Ford says it is suspending or cutting production at eight of its factories in North America through next week due to the shortage. Balu Balakrishnan, President and CEO of Power Integrations, joins Cheddar News' Closing Bell, where he elaborates on why the chip shortage has dragged into 2022.
Peloton has weathered a seemingly never-ending storm the past few months: PR blunders, sinking customer demand, and in recent weeks, reported cost-cutting and potential layoffs. Now, several companies are said to be in the mix as potential buyers: Amazon, Netflix, Disney, and Apple. How likely is it that one of these companies pursues a deal — and how likely is it that it will be Apple who buys Peloton? Dan Ives, Managing Director of Equity Research at Wedbush Securities, joins Closing Bell to discuss his thoughts about Apple pursuing a Peloton takeover,
Astra aborted the launch for NASA ELaNa 41 Mission out of Cape Canaveral on Monday due to what was described as a minor issue, but the company's stock fell nearly 14 percent following the news. Jim Cantrell, CEO and co-founder of Phantom Space, which builds and launches spacecraft of its own, joined Cheddar to discuss the scrubbed mission. “The last thing you want is for this to go wrong, you're better to err on the side of safety expectations,” Cantrell explained, noting that the mission delay was a normal event.
Dating app Bumble announced its first acquisition, expanding into Europe by picking up Fruitz, a French Platform. The Fruitz app allows its users to convey dating preferences through fruit metaphors.
Meat production giant Tyson Foods reported a beat on its Q1 earnings. In spite of obstacles posed by supply chain issues and inflation, the company exceeded expectations on earnings per share and revenue.
TC BioPharm, a biopharmaceutical company focused on developing cell therapy products targeting, went public on the Nasdaq in January. CEO Bryan Kobel joined Cheddar to talk about the company's IPO launch, its cancer-fighting therapeutics tech, and its potential for using its research to treat COVID-19. "The opportunity here for us is to really get safety data and covid and expand into other areas," Kobel said. "So from COVID, where we hope to treat patients, hopefully maybe the elderly population, populations that that really can't handle the antivirals because they're too hard in the system, well then we'll expand out into maybe severe influenza Ebola, other viral and viral infections where we think we can be helpful."
